Ontology highlight
ABSTRACT: Background
Mycobacterium abscessus is a non-tuberculous mycobacterium (NTM) that causes chronic pulmonary infections. Because of its extensive innate resistance to numerous antibiotics, treatment options are limited, often resulting in poor clinical outcomes. Current treatment regimens usually involve a combination of antibiotics, with clarithromycin being the cornerstone of NTM treatments.Objectives
To identify drug candidates that exhibit synergistic activity with clarithromycin against M. abscessus.Methods
We performed cell-based phenotypic screening of a compound library against M. abscessus induced to become resistant to clarithromycin. Furthermore, we evaluated the toxicity and efficacy of the top compound in a zebrafish embryo infection model.Results
The screen revealed rifaximin as a clarithromycin potentiator. The combination of rifaximin and clarithromycin was synergistic and bactericidal in vitro and potent in the zebrafish model.Conclusions
The data indicate that the rifaximin/clarithromycin combination is promising to effectively treat pulmonary NTM infections.
SUBMITTER: Goh BC
PROVIDER: S-EPMC10164658 | biostudies-literature | 2023 Jun
REPOSITORIES: biostudies-literature
Goh Boon Chong BC Larsson Simon S Dam Linh Chi LC Ling Yan Han Sharon YHS Chua Wei Lin Patrina WLP Abirami R R Singh Samsher S Ong Jun Long Ernest JLE Teo Jeanette W P JWP Ho Peiying P Ingham Philip W PW Pethe Kevin K Dedon Peter C PC
JAC-antimicrobial resistance 20230508 3
<h4>Background</h4><i>Mycobacterium abscessus</i> is a non-tuberculous mycobacterium (NTM) that causes chronic pulmonary infections. Because of its extensive innate resistance to numerous antibiotics, treatment options are limited, often resulting in poor clinical outcomes. Current treatment regimens usually involve a combination of antibiotics, with clarithromycin being the cornerstone of NTM treatments.<h4>Objectives</h4>To identify drug candidates that exhibit synergistic activity with clarit ...[more]